“…4 Dupilumab, an interleukin-4 (IL-4) alpha and IL-13 alpha receptors antagonist, is being explored as a novel therapeutic option for the treatment of eczema, with a less immunosuppressive effect than corticosteroids. 3 As demonstrated by these cases, dupilumab may be a new, useful and safe steroidsparing drug in oncologic patients suffering from ICIinduced eczema, but other studies will be necessary to confirm this theory.…”